Enzalutamide Receives Go Ahead From European Commission in nmHSPC
The European Commission has approved enzalutamide as monotherapy and in combination with ADT in BCR nonmetastatic hormone-sensitive prostate cancer.
The European Commission has approved enzalutamide as monotherapy and in combination with ADT in BCR nonmetastatic hormone-sensitive prostate cancer.
Abstract. AbstractGut-microbiota modulation shows promise in improving immune-checkpoint blockade (ICB) response; however, precision biomarker-driven, placebo-controlled trials are lacking. We performed a multicenter, randomized placebo-controlled, biomarker-stratified…
Unquestionably, a child’s cancer diagnosis weighs heavily on the parents’ minds. But now, an analysis of nearly 30,000 U.S. families has quantified how often parents…
Separating fact from fiction is an important tool when facing a brain tumor diagnosis
Response to updated vaccine is shaped by earlier vaccines yet generates broadly neutralizing antibodies
Sen. Richard J. Durbin (D-IL) has asked Amgen to provide copies of the company’s communications with FDA related to the dosage of Lumakras (sotorasib), a…
May 22, 2024: Meeting of the Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee Meeting Announcement
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of…
AbstractBackground:. The U.S. Preventive Services Task Force recently issued an updated draft recommendation statement to initiate breast cancer screening at age 40, reflecting well-documented disparities…
The healthcare sector’s necessary transition towards electronic health records (EHRs) has transformed patient care and operational efficiency. To access this subscriber-only content please log in…
PF-07220060 plus endocrine therapy was tolerable and generated robust response rates in HR-positive, HER2-negative metastatic breast cancer.